Viewing Study NCT00000863



Ignite Creation Date: 2024-05-05 @ 11:08 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00000863
Status: COMPLETED
Last Update Posted: 2021-10-28
First Post: 1999-11-02

Brief Title: A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia PCP in HIV-Infected Patients
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Organization: National Institute of Allergy and Infectious Diseases NIAID

Study Overview

Official Title: A Phase II Study of WR 6026 for Pneumocystis Carinii Pneumonia in People With HIV Infection
Status: COMPLETED
Status Verified Date: 2021-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To evaluate the efficacy of WR 6026 once daily in the treatment of mild PCP To evaluate the safety and tolerance of WR 6026 To assess the correlation between plasma WR 6026 concentrations and outcometoxicity
Detailed Description: All patients will receive an initial loading dose of WR 6026 followed the next morning and each morning thereafter by 1 of 2 lower doses of WR 6026 taken in a fasting state for 3 weeks

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
11289 REGISTRY DAIDS ES Registry Number None